RadioGel®

Precison Radionuclide Therapy™

Also known as PRnT, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. Vivos Inc. has developed a Yttrium-90 based injectable device to treat tumors in animals (IsoPet® Division).RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.

Radionuclide therapy, also known as nuclear medicine therapy or radiopharmaceutical therapy, involves the use of radioactive substances to treat diseases, most commonly cancer.

The therapy utilizes radionuclides, which are radioactive isotopes, attached to molecules that can specifically target cancer cells. This allows the radionuclides to deliver targeted radiation directly to the tumor or diseased area, minimizing damage to surrounding healthy tissue.

In this treatment, the radioactive isotopes emit radiation that damages the DNA of the targeted cells, leading to cell death or a significant reduction in the cell’s ability to multiply. The most familiar forms of radionuclide therapy include treatments for thyroid cancer using iodine-131, pain relief from bone metastases with strontium-89 or samarium-153, and peptide receptor radionuclide therapy (PRRT) for treating neuroendocrine tumors using radionuclide peptides. Vivos Inc. and their patented Precision Radionuclide Therapy™ uses Yttrium-90 to kill tumors and is revolutionizing the treatment of cancer.